Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines

Anticancer Research

Volumn 24, Issue 3 A, 2004, Pages 1745-1751

  Devy, Jérome ^a   Wargnier, Richard ^a   Pluot, Michel ^a   Nabiev, Igor ^a   Sukhanova, Alyona ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

Author keywords

DNA topoisomerase I; Down regulation; Solid tumor cell lines; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; IMMUNOGLOBULIN; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HT29; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; SOLID TUMOR; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; ENZYME STABILITY; FEMALE; HUMANS; LUNG NEOPLASMS; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; TOPOTECAN;

EID: 3242680748     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Wang JC: DNA topoisomerases. Annu Rev Biochem 65: 635-692, 1996.
2. Chen AY and Liu LF: DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34: 191-218, 1994.
3. Pommier Y, Tanizawa A and Kohn KW: Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv Pharmacol 29B: 73-92, 1994.
4. Kaufmann SH: Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1400: 195-211, 1998.
5. Potmesil M: Camptothecin: from bench research to hospital wards. Cancer Res 54: 1431-1439, 1994.
6. Jonsson E, Dhar S, Jonsson B, Nygren P, Graf W and Larsson R: Differential activity of topotecan, irinotecan and SN-38 in fresh human tumor cells but not in cell lines. Eur J Cancer 36: 2120-2127, 2000.
7. Huang CH and Treat J: New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors. Oncology 61: 14-24, 2001.
8. Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines. Eur J Cancer 36: 2120-7, 2000.
9. Saleem A, Edwards TK, Rasheed Z and Rubin E: Mechanism of resistance to camptothecins. Ann NY Acad Sci 922: 46-55, 2000.
10. Pommier Y, Pourquier P, Urasaki Y, Wu J and Laco GS: Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 2: 307-318, 1999.
11. Perego P, Capranico G, Supino R and Zunino F: Topoisomerase I gene expression and cell sensititvity to camptothecin in human cell lines of different tumor type. Anti Cancer Drugs 5: 645-649, 1994.
12. Li TK and Liu LF: Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 41: 53-77, 2001.
13. Samejima K, Svingen PA, Basi GS, Kottke T, Mesner PW Jr, Stewart L, Durrieu F, Poirier GG, Alnemri ES, Champoux JJ, Kaufmann SH and Earnshaw WC: Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis. J Biol Chem 274: 4335-4340, 1999.
14. Beidler DR and Cheng YC: Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol 47: 907-914, 1995.
15. Desai SD, Li TK, Rodrigues-Bauman A, Rubin EH and Liu LF: Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 61: 5926-5932, 2001.
16. Fu Q, Kim SW, Chen HX, Grill S and Cheng YC: Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitors structure but independent of cell death. Mol Pharmacol 55: 677-683, 1999.
17. Kudinov AR, Bronstein IB and Gabibov AG: Two subforms of eukaryotic topoisomerase I. Purification and structure-function relationships. FEBS Lett 314: 267-70, 1992.
18. Sun Z, Shen K and Xu X: The effect of hydrocamptothecin and topotecan to SKOV3 and CAOV3 in vitro. Zhongua Fu Chan Ke Za Zhi 34: 547-550, 1999.
19. Mathijssen RHJ, Loos WJ, Verweij J and Sparrenboom A: Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2: 103-123, 2002.
20. Zhou Y, Gwardry FG, Reinhold WC, Miller LD, Smith LH, Scherf U, Liu ET, Kohn KW, Pommier Y and Weinstein JN: Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res 62: 1688-1695, 2002.
21. Kaufmann SH and Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Experim Cell Res 256: 42-49, 2000.
22. Goldwasser F, Bae I, Valenti M, Torres K and Pommier Y: Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55: 2116-2121, 1995.
23. Pommier Y, Gupta M, Valenti M and Nieves-Neira W: Cellular resistance to camptothecins. Ann N Y Acad Sci 803: 60-73, 1996.
24. Nieves-Neira W and Pommier Y: Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int J Cancer 82: 396-404, 1999.
25. Janicke RU, Ng P, Sprengart ML and Porter AG: Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 273: 15540-15545, 1998.
26. Zapata JM, Krajewska M, Krajewski S, Huang RP, Takayama S, Wang HG, Adamson E and Reed JC: Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat 47: 129-140, 1998.
27. Dowlati A, Levitan N, Gordon NH, Hoppel CL, Gosky DM, Remick SC, Ingalls ST, Berger SJ and Berger NA: Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 47: 141-148, 2001.
28. Staley BE, Samowitz WS, Bronstein IB and Holden JA: Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon. Mod Pathol 12: 356-61, 1999.
29. Creemers GJ, Gerrits CJ, Schellens JH, Planting AS, van der Burg ME, van Beurden VM, de Boer-Dennert M, Harteveld M, Loos W, Hudson I, Stoter G and Verweij J: Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 14: 2540-2545, 1996.
30. Liu LF, Duann P, Lin CT, D'Arpa P and Wu J: Mechanism of action of camptothecin. Ann N Y Acad Sci 803: 44-49, 1996.